Outset sets record for delivery of Tablo dialysis machines
Click Here to Manage Email Alerts
Outset Medical, maker of the Tablo hemodialysis machine, reported that the device was added to 30 new hospital sites in the first quarter of 2023, marking the greatest quarterly growth in new sites in 2 years, according to a press release.
Net revenue for the company increased 4.6% vs. the last quarter of 2022, landing 9.5% higher than at the same time last year, the company said, totaling $33.5 million and leaving the company with $252.5 million in total cash as of March 31, according to the release.
“We had a strong start to 2023, with revenue growth ahead of our expectations and gross margins expanding for the eighth consecutive quarter,” Leslie Trigg, MBA, CEO of Outset Medical, said in the release. “The momentum we had exiting 2022 carried through the first quarter of 2023, with the benefits of Tablo continuing to resonate with acute-care and home providers.”
Outset projected 2023 revenue to ultimately total between $144 million and $150 million, which would exceed fiscal year 2022 revenue by about 25% to 30%, according to the release.
The FDA approved Tablo for home use in 2020. Outset paused shipments of Tablo systems for home use last year as the FDA weighed approval of technical changes made to the system since its initial clearance, according to a 2022 company press release.
Reference:
- Outset Medical resumes shipment of Tablo systems for home use, reports second quarter 2022 financial results and provides 2022 guidance. https://investors.outsetmedical.com/news-releases/news-release-details/outset-medical-resumes-shipment-tablo-systems-home-use-reports. Published Aug. 1, 2022. Accessed May 8, 2023.
Read more about
Click Here to Manage Email Alerts